Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 218.78M P/E - EPS this Y 26.30% Ern Qtrly Grth -
Income -30.58M Forward P/E -2.89 EPS next Y -3.10% 50D Avg Chg -1.00%
Sales - PEG 0.23 EPS past 5Y - 200D Avg Chg -24.00%
Dividend N/A Price/Book 3.55 EPS next 5Y -9.40% 52W High Chg -67.00%
Recommedations 1.60 Quick Ratio 1.87 Shares Outstanding 29.29M 52W Low Chg 18.00%
Insider Own 43.90% ROA -56.83% Shares Float 15.70M Beta 0.17
Inst Own 10.14% ROE -225.35% Shares Shorted/Prior 797.56K/738.66K Price 4.30
Gross Margin - Profit Margin - Avg. Volume 57,675 Target Price 11.75
Oper. Margin - Earnings Date Nov 8 Volume 27,639 Change -0.46%
About Rani Therapeutics Holdings, Inc

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings, Inc News
11/20/24 RANI: Third Quarter Update
11/14/24 Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
11/07/24 Rani Therapeutics to Participate in Upcoming Investor Conferences
10/23/24 Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch
10/22/24 RANI: New Triagonist Data in Weight Loss
10/17/24 Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
10/15/24 Top Midday Decliners
10/15/24 Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants
10/13/24 Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ Stocks
10/09/24 Pleasing Signs As A Number Of Insiders Buy Rani Therapeutics Holdings Stock
10/08/24 Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
09/03/24 Rani Therapeutics to Participate in September Investor Conferences
08/19/24 Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$12m last week
08/12/24 RANI: Second Quarter Results
08/06/24 Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
07/29/24 Rani Therapeutics to Participate in August Investor Conferences
07/22/24 Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
06/28/24 RANI: GLP-2 Deal Announced
06/24/24 Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
05/14/24 Rani Therapeutics to Participate in May Investor Conferences
RANI Chatroom

User Image ion07 Posted - 30 minutes ago

$BIOR $RANI "In November 2023, the Company’s Board of Directors (“Board”) approved a reduction in the annual salary of Talat Imran, the Company’s Chief Executive Officer, from $520,000 to $100,000, effective November 1, 2023 through December 31, 2024 or until such time as the Company receives gross proceeds of $50,000,000 or more, in the aggregate, from equity financing and/or one or more non-dilutive strategic, licensing or partnering transactions (the “Financing Threshold”). In November 2024, the Board approved to extend the reduction in annual salary of Talat Imran through December 31, 2025 or until the Financing Threshold is met."

User Image adubstrades Posted - 2 days ago

$GTBP $RANI

User Image CantNameThatTune Posted - 2 days ago

$RANI somebody messed up somewhere. This $GTBP soaring now on Roth giving it an $11 price Target. But if I'm not mistaken RANI has 14 price targets with an average of all over $12 a share Target. Still only $1.51

User Image Stmkr Posted - 3 days ago

$RANI "In November 2023, the Company’s Board of Directors (“Board”) approved a reduction in the annual salary of Talat Imran, the Company’s Chief Executive Officer, from $520,000 to $100,000, effective November 1, 2023 through December 31, 2024 or until such time as the Company receives gross proceeds of $50,000,000 or more, in the aggregate, from equity financing and/or one or more non-dilutive strategic, licensing or partnering transactions (the “Financing Threshold”). In November 2024, the Board approved to extend the reduction in annual salary of Talat Imran through December 31, 2025 or until the Financing Threshold is met."

User Image CallMeMyBeer Posted - 3 days ago

$RANI the partnership with random korean company "As part of this agreement, there is no upfront payment or financial exchange between the companies." tells you everything you need to know.

User Image Zackpedia Posted - 5 days ago

$RANI Up now but resistance at 1.37 for now, hit Follow to get my alerts on time for free and make money

User Image CantNameThatTune Posted - 5 days ago

$RANI Careful. Company might just announce licensing of RANI pill in a $100 million agreement with $AZN

User Image CantNameThatTune Posted - 5 days ago

$RANI down 9 straight sessions on no news. This level of complete idiocy takes high-level training

User Image Zackpedia Posted - 6 days ago

$RANI Watch this today, support at 1.27, buy the dip for the rip

User Image Bigblock6 Posted - 6 days ago

$RANI Wow this is a disgrace sorry to see this happen

User Image powerw Posted - 6 days ago

$RANI anyone know what the price was at 3:30 in the morning I noticed it went down about 12%

User Image CantNameThatTune Posted - 6 days ago

$RANI heard in the Town Square... "I've been using RainyPill in the trials for 28 weeks and lost 80 lbs. This is a miracle drug."

User Image CantNameThatTune Posted - 6 days ago

$RANI One would think RANI would be flying along with BPTH on this news. RANI has a clear path to FDA approval for RaniPill. An oral weight loss drug at a fraction of the price of Wegovy and Ozempic.

User Image CantNameThatTune Posted - 1 week ago

$RANI Talat? You need to take the buyout offer

User Image CallMeMyBeer Posted - 1 week ago

$RANI nobody cares about the pills. Look at the all time lows.

User Image Tooneyman Posted - 1 week ago

Come on baby you can do it! ... Come on baby! ... For the love of God, raise the freaking stock price!! NOW!!! $RANI

User Image I_am_retail_investor Posted - 1 week ago

$RANI hmm what is RANI management doing about their falling marketcap? Retail wants to know!

User Image Zackpedia Posted - 1 week ago

$RANI Buying alert at 1.39!

User Image Tooneyman Posted - 1 week ago

$RANI Ozempic may be in trouble ..... https://www.cnbc.com/2024/12/17/healthy-returns-ozempic-faces-scrutiny-over-potential-eye-condition-risk.html

User Image CantNameThatTune Posted - 1 week ago

$RANI you see what $PLRZ $TCBP $CGTX are all doing soaring on trial news. RANI released RANI pill oral weight loss data on 12/14/23 and will release another huge update at any moment. It could send ROs Wegovy and Ozempic into a tailspin for an immediate IND

User Image CantNameThatTune Posted - 1 week ago

$RANI Something big is brewing. This kind of buying does not create all time lows

User Image CantNameThatTune Posted - 1 week ago

$RANI This from the company exactly one year ago. The news moved the stock from $3.85 to $8.75. There is absolutely no news to account for these all time lows at $1.50. This now looks identical to $VYGR down under $2 and then up over $11. More great news for RANI as early as today.

User Image ronaldo7 Posted - 1 week ago

$RANI 10k shares @ $1.465

User Image CantNameThatTune Posted - 1 week ago

$RANI This company has not said one single thing negative. Not quite sure how this can possibly continue to keep going down every day setting new all time lows on no bad news.

User Image CantNameThatTune Posted - 1 week ago

$RANI it's all over the TV. The USA has just experienced its first drop in the obesity rate in over 10 years. They are equating it to successful drugs like Ozempic and Wegovy. They are pushing for immediate Medicare approval for these drugs. This will most definitely push big pharma to make buyout offers for other companies that have weight loss drugs identical to these and development. That would be RANI.

User Image PenkeTrading Posted - 1 week ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Rani Therapeutics Holdings Inc. Is that bullish or bearish? $RANI #Rani #RsiOversold #NASDAQ

User Image Tooneyman Posted - 1 week ago

$RANI I don't get it. Several analysts say the average price for RANI is around $12 to $14. Why is the stock at $1.66 today and still sinking?? WTF??

User Image RichT844 Posted - 1 week ago

$RANI the 14 analysts know nothing. That is what the market is telling me.

User Image CallMeMyBeer Posted - 1 week ago

$RANI all time low. Not good

User Image CantNameThatTune Posted - 1 week ago

$RANI hard to believe 14 analysts with an average price target of $14 on RANI are all wrong.

Analyst Ratings
HC Wainwright & Co. Buy Aug 16, 24
Oppenheimer Outperform Aug 2, 24
HC Wainwright & Co. Buy Jun 25, 24
Maxim Group Buy Jun 14, 24
Rodman & Renshaw Buy Jun 13, 24
BTIG Buy May 9, 24
HC Wainwright & Co. Buy May 7, 24
Canaccord Genuity Buy Mar 27, 24
HC Wainwright & Co. Buy Mar 25, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Imran Talat Chief Executive Offi.. Chief Executive Officer Dec 06 Buy 2.27 10,000 22,700 484,455 12/07/23
Imran Talat Chief Executive Offi.. Chief Executive Officer Dec 04 Buy 2.57 5,000 12,850 474,455 12/06/23
Imran Talat Chief Executive Offi.. Chief Executive Officer Nov 29 Buy 2.05 20,000 41,000 469,455 12/01/23
Nanavaty Maulik Director Director Nov 16 Buy 1.98 500 990 500 11/20/23
South Cone Investments Limited... 10% Owner 10% Owner May 03 Buy 4.8118 2,040 9,816 6,856,714 05/05/23
South Cone Investments Limited... 10% Owner 10% Owner Apr 24 Buy 4.59 8,703 39,947 6,852,501 04/26/23
South Cone Investments Limited... 10% Owner 10% Owner Apr 20 Buy 5.13 5,950 30,524 6,843,798 04/24/23
South Cone Investments Limited... 10% Owner 10% Owner Apr 18 Buy 5.3724 1,850 9,939 6,837,848 04/20/23
South Cone Investments Limited... 10% Owner 10% Owner Apr 14 Buy 5.2704 1,901 10,019 6,835,998 04/18/23
South Cone Investments Limited... 10% Owner 10% Owner Apr 10 Buy 5.32 3,688 19,620 6,829,630 04/12/23
South Cone Investments Limited... 10% Owner 10% Owner Apr 04 Buy 5.49 11,696 64,211 6,818,391 04/06/23
South Cone Investments Limited... 10% Owner 10% Owner Mar 28 Buy 5.4937 3,510 19,283 6,790,127 03/30/23
South Cone Investments Limited... 10% Owner 10% Owner Mar 20 Buy 6.19 3,762 23,287 6,786,617 03/22/23
South Cone Investments Limited... 10% Owner 10% Owner Mar 16 Buy 6.13 4,305 26,390 6,782,855 03/20/23
South Cone Investments Limited... 10% Owner 10% Owner Mar 13 Buy 6.1391 2,463 15,121 6,778,550 03/15/23
South Cone Investments Limited... 10% Owner 10% Owner Feb 28 Buy 6.2986 711 4,478 6,765,655 03/02/23
South Cone Investments Limited... 10% Owner 10% Owner Feb 21 Buy 6.02 4,080 24,562 6,755,952 02/23/23
South Cone Investments Limited... 10% Owner 10% Owner Feb 14 Buy 5.23 19,250 100,678 6,733,904 02/16/23
South Cone Investments Limited... 10% Owner 10% Owner Dec 29 Buy 5.97 17,200 102,684 6,714,654 01/03/23
Quiroga Cortes Isidoro Alfonso 10% Owner 10% Owner Dec 30 Buy 6.0258 8,400 50,617 5,271,378 01/03/23
South Cone Investments Limited... 10% Owner 10% Owner Dec 16 Buy 7.6 13,300 101,080 6,688,297 12/20/22
South Cone Investments Limited... 10% Owner 10% Owner Dec 12 Buy 8.13 24,550 199,592 6,658,678 12/14/22
South Cone Investments Limited... 10% Owner 10% Owner Dec 08 Buy 7.97 24,540 195,584 6,634,128 12/12/22
South Cone Investments Limited... 10% Owner 10% Owner Dec 02 Buy 8.06 22,014 177,433 6,596,488 12/06/22
South Cone Investments Limited... 10% Owner 10% Owner Nov 30 Buy 7.96 8,202 65,288 6,574,474 12/02/22
South Cone Investments Limited... 10% Owner 10% Owner Nov 28 Buy 7.9536 3,720 29,587 6,566,272 11/30/22
South Cone Investments Limited... 10% Owner 10% Owner Nov 18 Buy 7.56 29,000 219,240 6,558,356 11/23/22
IMRAN MIR A Director Director Aug 17 Sell 11.07 80,252 888,390 66,445 08/19/22
Farquharson Andrew Director Director Aug 17 Sell 11.07 80,252 888,390 65,124 08/19/22